Source: Yahoo

ASP Isotopes: ASP Isotopes Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

In This Article: ASP Isotopes ( NASDAQ:ASPI ) Full Year 2024 Results Key Financial Results Net loss: US$35.1m (loss widened by 116% from FY 2023). US$0.63 loss per share (further deteriorated from US$0.49 loss in FY 2023). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. NasdaqCM:ASPI Earnings and Revenue Growth April 2nd 2025 All figures shown in the chart above are for the trailing 12 month (TTM) period ASP Isotopes Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 11%. Looking ahead, revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in the US. Performance of the American Chemicals industry. The company's shares are up 5.9% from a week ago. Risk Analysis You should learn about the 3 warning signs we've spotted with ASP Isotopes (including 2 which are a bit unpleasant) . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. NasdaqCM:ASPI Earnings and Revenue Growth April 2nd 2025

Read full article »
Annual Revenue
$100K-5.0M
Employees
25-100
CEO Avatar

Chairman & CEO

Paul E Mann

CEO Approval Rating

- -/100